Gilead Sciences, Inc. (NASDAQ:GILD) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET
Company Participants
Daniel O'Day - Chairman, Chief Executive Officer
Johanna Mercier - Chief Commercial Officer
Merdad Parsey - Chief Medical Officer
Andrew Dickinson - Chief Financial Officer
Jackie Ross - Vice President, Investor Relations, Corporate Strategic Finance
Cindy Perettie - Executive Vice President of Kite
Conference Call Participants
Courtney Breen - Bernstein
Mike Yee - Jeffries
Umer Raffat - Evercore
Tyler Van Buren - TD Cowen
Daina Graybosch - Leerink Partners
Carter Gould - Barclays
Chris Schott - JP Morgan
Salveen Richter - Goldman Sachs
Matt Biegler - Oppenheimer
Karina Rabayeva - Truist
Brian Abrahams - RBC Capital Markets
Operator
Good afternoon, everyone, and welcome to Gilead's Third Quarter 2024 Earnings Conference Call. My name is Rebecca, and I'll be your host for today. In a moment we'll begin with our prepared remarks, followed by our Q&A session. [Operator Instructions].
I'll now hand the call over to Jackie Ross, Vice President of Investor Relations and Corporate Strategic Finance.
Jackie Ross
Thank you, Rebecca. Just after market close today, we issued a press release with earnings results for the third quarter of 2024. The press release, slides and supplementary data are available on the Investors section of our website at gilead.com.
The speakers on today's call will be our Chairman and Chief Executive Officer, Daniel O'Day; our Chief Commercial Officer, Johanna Mercier; our Chief Medical Officer, Merdad Parsey, and our Chief Financial Officer, Andrew Dickinson. After that, we'll open the call to Q&A, where the team will be joined by Cindy Perettie, the Executive Vice President of Kite.
Before we get started, let me remind you that we will be making forward-looking statements. Please refer to Slide 2 regarding the risks and uncertainties relating to forward-looking statements that could cause actual results to differ materially.
With that, I'll turn the call over to Dan.
Daniel O'Day
Thank you, Jackie. And good afternoon, everyone. The team and I are pleased to share Gilead's third quarter results, highlighting another very strong quarter of commercial and operational execution with robust year-over-year revenue performance across HIV, Oncology, and Liver Disease, including 9% growth in HIV.
We also delivered strong bottom-line results that highlight the leverage in our business model and reflect our ongoing commitment to disciplined expense management. Based on our financial results year-to-date, we are increasing our 2024 guidance across almost every metric, including revenue and non-GAAP gross margin, operating income, and EPS.